Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.45 -0.08 (-0.15%)

Streaming Delayed Price Updated: 10:43 AM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

Via PredictStreet

Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market

December 23, 2025

Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded...

Via MarketMinute

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Via The Motley Fool

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗

November 30, 2025

The comeback may have begun.

Via The Motley Fool

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗

November 18, 2025

"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.

Via Benzinga

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗

November 18, 2025

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Via Stocktwits

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why ↗

November 18, 2025

Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.

Via Benzinga

Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗

November 18, 2025

The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow.

Via Investor's Business Daily

Topics Government

2 No-Brainer Healthcare Stocks to Buy Now ↗

November 18, 2025

These two healthcare stocks scan as bargains right now.

Via The Motley Fool

Magnificent Seven Will Become Low-Profit Tech Utilities, Analyst Warns ↗

November 17, 2025

Magnificent Seven, beware. Kai Wu says Wall Street's AI darlings are shifting toward a riskier, capital-heavy model.

Via Benzinga

Topics Artificial Intelligence

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗

November 17, 2025

Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug.

Via Investor's Business Daily

Why Roche Holding Stock Popped Today ↗

November 10, 2025

Roche is great at developing drugs -- but is its stock a great buy?

Via The Motley Fool

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗

November 10, 2025

Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.

Via Investor's Business Daily

Multimodal AI Unleashes New Era in Cancer Research: A Revolution in Diagnosis and Treatment

November 10, 2025

Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized...

Via TokenRing AI

Topics Artificial Intelligence

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year. ↗

November 05, 2025

The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%.

Via Investor's Business Daily

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Via TokenRing AI

Topics Artificial Intelligence

AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future

October 31, 2025

The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

S&P 500's Resurgence: A Deep Dive into Market Dynamics and Future Trajectories

October 23, 2025

The S&P 500 has staged a remarkable rebound, soaring to unprecedented highs in late 2025 following a period of significant sell-off earlier in the year. This resurgence, driven by a powerful confluence...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗

October 20, 2025

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.

Via Benzinga

Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results ↗

October 20, 2025

The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients.

Via Investor's Business Daily

Topics Government

Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche ↗

October 20, 2025

The company took on Roche's Xolair in a 16-week study of patients with a chronic hives disorder.

Via Investor's Business Daily

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients ↗

October 16, 2025

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.

Via Benzinga

FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly ↗

October 13, 2025

The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older.

Via Stocktwits

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout ↗

October 09, 2025

The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company.

Via Investor's Business Daily

Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market ↗

October 09, 2025

Roche has a promising GLP-1 drug that is entering phase 3 trials.

Via The Motley Fool

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

October 03, 2025

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca...

Via MarketMinute

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.